Table 3.
Case reports and case series of coronavirus disease 2019 infection in lymphoma patients
| Ref. | No. of patients described | Sex | Age | Details on lymphoma diagnosis | Details on lymphoma treatment | Outcome of COVID-19 infection | Global outcome |
| Li et al[61], 2020 | 1 | M | 26 yr | PMLBCL | R-DA-EPOCH | Recovered | Alive |
| Tepasse et al[62], 2020 | 2 | M | 65 yr | DLBCL with CNS relapse | R-DeVIC | Not recovered | Dead |
| M | 66 yr | MCL in CR | Rituximab maintenance | Not recovered | Dead | ||
| O'Kelly et al[63], 2020 | 1 | cHL second relapse | Pembrolizumab | Recovered | Alive | ||
| Baang et al[64], 2021 | 1 | M | 60 yr | Relapsed/Refractory MCL | R-CHOP | Recovered | Alive |
| Moore et al[65], 2020 | 1 | F | 63 yr | NHL | Obinotuzumab maintenance | Recovered | Alive |
| Alsuliman et al[66], 2020 | 2 | M | 71 yr | MCL relapsed | Ibrutinib | Recovered | Alive |
| M | NR | MCL relapsed | Ibrutinib | Recovered | Alive | ||
| Hoffmann et al[67], 2021 | 3 | F | 68 yr | DLBCL, FL | R-CHOP | Recovered | Alive |
| M | 60 yr | DLBCL, FL | R-ICE | Not recovered | Dead | ||
| M | 75 yr | DLBCL | R-CHOP | Not recovered | Dead | ||
| Yonal-hindilerden et al[68], 2021 | 1 | F | 55 yr | Relapsed/Refractory cHL | Brentuximab | Not recovered | Dead |
| Fujii et al[69], 2021 | 1 | M | 43 yr | cHL | A + AVD | Recovered | Alive |
| Kamel, 2021 | 1 | M | 58 yr | ALCL | None | Not recovered | Dead |
| Santana et al[70], 2021 | 1 | F | 47 yr | FL | Rituximab maintenance | Recovered | Alive |
| Velier et al[71], 2021 | 1 | F | 61 yr | WM | None | Recovered | Dead |
| Pelcovits et al[72], 2021 | 1 | M | 43 yr | High Grade B Cell Lymphoma, NOS | R-CODOX-M/IVAC | Recovered | Alive |
| Otsuka et al[73], 2020 | 1 | M | 56 yr | MCL | R-hyper CVAD/MA | Not recovered | Dead |
A + AVD: Brentuximab vedotin, dacarbazine, doxorubicin, vinblastine; ALCL: Anaplastic large-cell lymphoma; cHL: Classic Hodgkin lymphoma; CNS: Cerebral nervous system; COVID-19: Coronavirus disease 2019; CR: Complete remission; DLBCL: Diffuse large B-cell lymphoma; F: Female; FL: Follicular lymphoma; M: Male; MCL: Mantle cell lymphoma; NHL: Non-Hodgkin lymphoma; NOS: Not otherwise specified; PMLBCL: Primary mediastinal large B-cell lymphoma; R-CHOP: Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; R-CODOX-M/IVAC: Rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate alternating with ifosfamide, etoposide and cytarabine; R-DA-EPOCH: Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin and rituximab; R-DeVIC: Rituximab, dexamethasone, etoposide, ifosfamide carboplatin; R-hyper CVAD/MA: Rituximab/cyclophosphamide/vincristine sulfate/doxorubicin and hydrochloride/dexamethasone/methotrexate/cytarabine; R-ICE: Rituximab, ifosfamide, carboplatin and etoposide; WM: Waldenstrom macroglobulinemia.